Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole

被引：1
|
作者：
Fleischhacker, W. W. [1 ]
Sanchez, R. [2 ]
Jin, N. [3 ]
Peters-Strickland, T. [2 ]
Johnson, B. R. [4 ]
Eramo, A. [5 ]
Loze, J. Y. [6 ]
McQuade, R. D. [7 ]
Carson, W. H. [8 ]
Kane, J. [9 ,10 ]
机构：
[1] Med Univ Innsbruck, Dept Psychiat & Psychotherapy, A-6020 Innsbruck, Austria
[2] Otsuka Pharmaceut Dev & Commercializat Inc, Global Clin Dev CNS, Princeton, NJ USA
[3] Otsuka Pharmaceut Dev & Commercializat Inc, Biostat, Rockville, MD USA
[4] Otsuka Pharmaceut Dev & Commercializat Inc, Clin Management, Princeton, NJ USA
[5] H Lundbeck & Co AS, Med Affairs & Phase Clin Affairs 4, Deerfield, IL USA
[6] Otsuka Pharmaceut Europe Ltd, European CNS Market Access, London, England
[7] Otsuka Pharmaceut Dev & Commercializat Inc, Global Med Regulatory Affairs & Alliances, Princeton, NJ USA
[8] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA
[9] Zucker Hillside Hosp, Glen Oaks, NY USA
[10] Hofstra North Shore LIJ Sch Med, Dept Psychiat, Glen Oaks, NY USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2013年 / 23卷
关键词：
D O I：
10.1016/S0924-977X(13)70751-X
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.028
引用
收藏
页码：S474 / S475
页数：2
相关论文
共 50 条
  • [21] Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia
    Feng, Yuan
    Shi, Jianguo
    Wang, Lili
    Zhang, Xia
    Tan, Yunlong
    Zhao, Jingyuan
    Ning, Yuping
    Xie, Shiping
    Liu, Xuejun
    Liu, Qi
    Li, Keqing
    Wang, Xiaoliang
    Li, Lehua
    Xu, Xiufeng
    Deng, Wei
    Luo, Xiaoyan
    Wang, Gang
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2020, 74 (06) : 336 - 343
  • [22] Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
    Daniel Schöttle
    Wolfgang Janetzky
    Daniel Luedecke
    Elmar Beck
    Christoph U. Correll
    Klaus Wiedemann
    BMC Psychiatry, 18
  • [23] SAFETY AND TOLERABILITY OF ARIPIPRAZOLE ONCE-MONTHLY INITIATED IN ADULTS WITH SCHIZOPHRENIA STABILIZED ON ATYPICAL ORAL ANTIPSYCHOTICS OTHER THAN ARIPIPRAZOLE
    Potkin, S.
    Raoufinia, A.
    Mallikaarjun, S.
    Bricmont, P.
    Peters-Strickland, T.
    Kasper, W.
    Jin, N.
    Baker, R. A.
    Eramo, A.
    Sanchez, R.
    McQuade, R. D.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [24] Effects of Paliperidone Palmitate 3 Month and 1 Month Formulations on Personal and Social Performance Scores in Patients with Schizophrenia: Results from a Randomized, Multicenter, Double-Blind, Non-inferiority Study
    Savitz, Adam
    Xu, Haiyan
    Mathews, Maju
    Nuamah, Isaac
    Gopal, Srihari
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 212S - 212S
  • [25] Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study
    Calabrese, Joseph
    Sanchez, Raymond
    Jin, Na
    Amatniek, Joan
    Cox, Kevin
    Johnson, Brian
    Perry, Pamela P.
    Hertel, Peter
    Such, Pedro
    Salzman, Phyllis M.
    McQuade, Robert D.
    Nyilas, Margaretta
    Carson, William H.
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S360 - S361
  • [26] The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study
    Calabrese, Joseph R.
    Sanchez, Raymond
    Jin, Na
    Amatniek, Joan
    Cox, Kevin
    Johnson, Brian
    Perry, Pamela P.
    Hertel, Peter
    Such, Pedro
    McQuade, Robert D.
    Nyilas, Margaretta
    Carson, William H.
    JOURNAL OF AFFECTIVE DISORDERS, 2018, 241 : 425 - 432
  • [27] PALIPERIDONE PALMITATE 3-MONTHLY COMPARED WITH 1-MONTHLY FORMULATION IN PATIENTS WITH SCHIZOPHRENIA: GLOBAL AND ASIAN SUBPOPULATION ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY STUDY
    Savitz, A.
    Gopal, S.
    Feng, Y.
    Xu, H.
    Zhuo, J.
    Yu, L.
    Nuomah, I.
    Ravenstijn, P.
    Wu, C.
    Hough, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2016, 50 : 166 - 167
  • [28] Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study
    Naber, Dieter
    Baker, Ross A.
    Eramo, Anna
    Forray, Carlos
    Hansen, Karina
    Sapin, Christophe
    Peters-Strickland, Timothy
    Nylander, Anna-Greta
    Hertel, Peter
    Schmidt, Simon Nitschky
    Loze, Jean-Yves
    Potkin, Steven G.
    SCHIZOPHRENIA RESEARCH, 2018, 192 : 205 - 210
  • [29] Cinnovex vs. Avonex: a double-blind, randomized, non-inferiority trial, preliminary results
    Nafissi, Shahriar
    Azimi, Amir Reza
    Majidzadeh, Keivan
    Mahboudi, Fereidoun
    MULTIPLE SCLEROSIS, 2008, 14 : S168 - S168
  • [30] The effect of previous dose of oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: Post-hoc analysis of two double-blind, randomized, controlled trials
    Nylander, A. -G.
    Eramo, A.
    Baker, R.
    Tsai, L. -F.
    Peters-Strickland, T.
    Sanchez, R.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 149 - 150
12345